Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Wai Chun Bio-Technology's highest 3-Year average EPS without NRI Growth Rate was 70.20% per year. The lowest was -50.90% per year. And the median was 24.90% per year.
Wai Chun Bio-Technology (HKSE:00660) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Wai Chun Bio-Technology EPS (Diluted) Related Terms
Wai Chun Bio-Technology EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Wai Chun Bio-Technology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wai Chun Bio-Technology PE Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Wai Chun Bio-Technology's PE Ratio distribution charts can be found below:
* The bar in red indicates where Wai Chun Bio-Technology's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Wai Chun Bio-Technology's Diluted EPS for the fiscal year that ended in Jun. 2025 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wai Chun Bio-Technology (HKSE:00660) has a EPS (Diluted) of HK$-0.04 as of Dec. 2025. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Wai Chun Bio-Technology and its competitors.
Is Wai Chun Bio-Technology's EPS (Diluted) too high?
Wai Chun Bio-Technology's current EPS (Diluted) is HK$-0.04. Overall, Wai Chun Bio-Technology has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Wai Chun Bio-Technology's EPS (Diluted) compare to DOW?
Wai Chun Bio-Technology's EPS (Diluted) of HK$-0.04 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Chemicals company?
A good EPS (Diluted) depends on the Chemicals industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Wai Chun Bio-Technology and its competitors. Wai Chun Bio-Technology's current EPS (Diluted) is HK$-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wai Chun Bio-Technology stock overvalued right now?
Wai Chun Bio-Technology (HKSE:00660) has a current EPS (Diluted) of HK$-0.04. The current EPS (Diluted) is HK$-0.04. Wai Chun Bio-Technology's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Wai Chun Bio-Technology (HKSE:00660), the current EPS (Diluted) is HK$-0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wai Chun Bio-Technology Ltd is an investment holding company. The company has one reportable segmentbeing the manufacturing and sale of modified starch and other biochemical products. It is involved in the manufacturing and sale of modified starch and other biochemical products. Geographically, it derives a majority of its revenue from the People's Republic of China. The company also has its presence in Hong Kong.
23GF Score
Get the complete analysis for HKSE:00660
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00660 has been successfully added to your 
